世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

会員登録

マイページ

3Dバイオプリンティング 2017-2027年:技術、市場、予測:コスメ、消費者向け製品テスト、薬品開発、再生医療の市場機会

3D Bioprinting 2017-2027: Technology, Markets and Forecasts

Opportunities in cosmetics and consumer product testing, drug development and regenerative medicine

 

出版社 出版年月電子媒体価格ページ数
IDTechEx
アイディーテックエックス
2017年5月GBP3,565
電子ファイル(1-5ユーザライセンス)
184

サマリー

この調査レポートは、3Dバイオプリンティング(バイオ印刷)の各技術とそのサブタイプの仕様やベンダ、SWOT分析などを掲載しています。また、電界紡糸(エレクトロスピニング)、光学バイオプリンティング、ラベルレス磁気浮上、音響浮揚などの実現技術についても掲載しています。

主な掲載内容 

印刷技術

  • インクジェット
  • 押出し
  • レーザー誘起前方転写法
  • マイクロ弁

現在、将来の3Dバイオプリンティングの用途

  • 化粧品、消費者向け製品のテスト
  • 医薬品スクリーニング
  • 個人向け医療
  • 再生医療
  • 細胞単位のバイオセンサ
  • 食品とその他の動物性食品
  • 教育
  • 学的研究
  • 生体工学(バイオニクス)

再生医療の組織タイプ

  • 骨と軟骨
  • 皮膚
  • 血管系
  • 複雑な臓器

Report Details

 Interest in 3D bioprinting has been gaining momentum in recent years, both in the academic and commercial settings. Between 2014 and 2015, the market welcomed numerous 3D bioprinting companies, and new start-ups, spin-outs, and subsidiaries are continuing to emerge. Though investment in the field has been driven on by the futuristic goal of providing solutions for regenerative by way of fabricating organs for transplant, more realistic applications in product development and testing have shown great promise and are already being marketed. Over 2016, several 3D bioprinting companies saw a doubling of revenue, and comparable results are anticipated for the next few years. Given these market trends, IDTechEx forecasts that the global market for 3D bioprinting will reach a value of $1.8 billion by the year 2027.

 
 
Source: IDTechEx
 
Technology and Applications
3D bioprinting can be defined in a variety of ways, and each definition includes and excludes large swathes of key biotechnology markets. In this report, IDTechEx has defined 3D bioprinting as the deposition of living cells in a spatially controlled manner in the absence of any pre-existing scaffold and in more than a single layer. Under this definition, 3D bioprinters are currently based on four main printhead technologies:
 
  • Inkjet
  • Extrusion
  • Laser-induced forward transfer
  • Microvalve
 
This report profiles each technology and its subtypes, and provides key specifications, vendors, and SWOT analyses. This report also introduces and discusses emerging 3D bioprinting technologies of electrospinning, optical bioprinting, label-less magnetic levitation, and acoustic levitation. Technologies and considerations relevant to the 3D bioprinting process, such as software, bioink (including cell selection, growth factors, and scaffold materials), and post-printing maturation are also discussed.
 
Current and future applications for 3D bioprinting discussed in this report include:
 
  • Testing of cosmetics and other consumer goods
  • Drug screening
  • Personalised medicine
  • Regenerative medicine
  • Cell-based biosensors
  • Food and other animal products
  • Education
  • Academic research
  • Bionics
 
Regenerative Medicine
Special attention is paid to regenerative medicine in this report, as not only does it have the potential to be the largest application for 3D bioprinting in the future, but also one with the highest impact. This report analyses how 3D bioprinting can be applied to regenerative medicine, and focuses on the following tissue types:
 
  • Bone and cartilage
  • Skin
  • Dental
  • Vasculature
  • Complex organs
 
Additionally, discussion of current progress in bringing 3D bioprinted tissues to the clinic is provided, as well future hurdles to be faced. A roadmap of 3D bioprinting in regenerative medicine to the year 2050 is provided.
 
Forecasts
This report forecasts the overall 3D bioprinting market to 2027, with in depth discussion of key trends in the short term (2017 - 2021), and those expected in the long term (2022 - 2027). Market forecasts to 2027 are also provided for the 3D bioprinter market segmented by price point, and the 3D bioprinted tissue market segmented by tissue application.


目次

Table of Contents

1. EXECUTIVE SUMMARY
1.1. Overview
1.2. 3D Bioprinting Players
1.3. High Profile Partnerships
1.4. Successful Animal Tests
1.5. 3D Bioprinting Market Forecast 2017 - 2027
1.6. 3D Bioprinter Market Forecast 2017 - 2027
1.7. 3D Bioprinted Tissue Market Forecast 2017 - 2027
1.8. Key Drivers
1.9. Key Challenges
2. INTRODUCTION
2.1. Report Scope / 3D Bioprinting Definition
2.2. 3D Bioprinting Process
2.2.1. 3D Bioprinting Process: Discussion
2.3. 3D Cell Culture Advantages
2.4. 3D Bioprinting Advantages
2.5. Key Driver: Regenerative Medicine
2.5.1. Key Driver: Unmet Need in Organs for Transplant
2.6. Key Driver: Product Testing in Medicine
2.6.1. Key Driver: Avoiding Costly Drug Trial Failures
2.7. Key Driver: Product Testing in Consumer Products
2.8. Major Bioprinting Firsts
2.9. 3D Bioprinting in 2017
2.10. Key Trends: 3D Bioprinters
2.11. Key Trends: Bioprinted Tissues
2.12. Key Competing Technologies
2.13. Current Technical Challenges
2.14. Current Biological Challenges
2.15. Regulatory Hurdles
2.16. 3D Bioprinting SWOT Analysis
3. 3D BIOPRINTER TECHNOLOGIES
3.1. From 3D Printing to 3D Bioprinting
3.2. 3D Bioprinting Technologies
3.2.1. Comparison of Key Specifications
3.3. 3D Bioprinting Technology Comparison
3.4. Inkjet: Introduction
3.4.1. Inkjet: Key Specifications
3.4.2. Inkjet: Thermal
3.4.3. Inkjet: Piezoelectric
3.4.4. Inkjet: Advantages
3.4.5. Inkjet: Challenges
3.4.6. Inkjet: SWOT Analysis
3.5. Extrusion: Introduction
3.5.1. Extrusion: Key Specifications
3.5.2. Extrusion: Pneumatic
3.5.3. Extrusion: Mechanical
3.5.4. Extrusion: Advantages
3.5.5. Extrusion: Challenges
3.5.6. Extrusion: SWOT Analysis
3.6. Laser: Introduction
3.6.1. LIFT: Key Specifications
3.6.2. LIFT: Laser-Induced Forward Transfer
3.6.3. LIFT: Advantages
3.6.4. LIFT: Challenges
3.6.5. LIFT: SWOT Analysis
3.7. Microvalve: Introduction
3.7.1. Microvalve: Key Specifications
3.7.2. Microvalve: Solenoid
3.7.3. Microvalve: Advantages
3.7.4. Microvalve: Challenges
3.7.5. Microvalve: SWOT Analysis
3.8. Emerging Technology
3.8.1. Emerging Technology: Electrospinning
3.8.2. Emerging Technology: Microscale Continuous Optical Bioprinting (µCOB)
3.8.3. Emerging Technology: Paramagnetic and Acoustic
3.9. Industry-wide Technical Challenges
3.10. The Ideal 3D Bioprinter
3.11. Future Technological Directions
4. RELATED TECHNOLOGIES
4.1. Related Technologies
4.2. 3D Bioprinting Software
4.3. Bioink Preparation
4.4. Cell Selection
4.5. Cell Selection: Regenerative Medicine
4.6. Growth Factors and Other Additives
4.7. Scaffold Materials
4.8. The Ideal Scaffold Material
4.9. Cell Spheroid Printing
4.10. Maturation
5. APPLICATIONS
5.1. Introduction
5.2. Testing of Cosmetics and Other Consumer Goods
5.3. Drug Screening
5.3.1. Drug Screening: Drug Development Process
5.4. Drug Screening: Benefits of 3D Bioprinting
5.5. Personalised Medicine
5.6. Regenerative Medicine
5.6.1. Regenerative Medicine: Tissue Roadmap
5.6.2. Regenerative Medicine: Bone and cartilage
5.6.3. Regenerative Medicine: Skin
5.6.4. Regenerative Medicine: Dental
5.6.5. Regenerative Medicine: Vasculature
5.6.6. Regenerative Medicine: Complex Organs
5.7. Cell-Based Biosensors
5.8. Food and Other Animal Products
5.9. Education
5.10. Academic Research
5.11. Bionics
6. MARKETS AND FORECASTS
6.1. Introduction
6.2. Growing 3D Bioprinting Market
6.3. Market Barriers
6.4. Key Losers
6.5. Forecasts
6.6. Overall 3D Bioprinting Market Forecast 2017 - 2017
6.6.1. Overall 3D Bioprinting Market Forecast: Short and Long Term
6.7. 3D Bioprinting Value Chain
6.7.1. 3D Bioprinting Value Chain: Discussion
6.8. 3D Bioprinter Manufacturers
6.8.1. 3D Bioprinters by Cost and Technology
6.9. 3D Bioprinter Market Forecast 2017 - 2027
6.9.1. 3D Bioprinter Market Forecast: Short Term
6.9.2. 3D Bioprinter Market Forecast: Long Term
6.10. 3D Bioprinting Service Bureaus
6.11. 3D Bioprinted Tissue Forecast 2017 - 2027
6.11.1. 3D Bioprinted Tissue Forecast: Consumer Products
6.11.2. 3D Bioprinted Tissue Forecast: Pharmaceuticals
6.11.3. 3D Bioprinted Tissue Forecast: Others
7. REGENERATIVE MEDICINE
7.1. Introduction
7.2. Regulatory Hurdles
7.3. Regenerative Medicine Advanced Therapy Designation
7.4. Ethics
7.5. Scams and Schemes
7.6. From Lab to Clinic
7.7. 3D Bioprinting Roadmap to 2050
8. APPENDIX
8.1. List of 3D Bioprinting Companies
8.2. List of Company Profiles
8.2.1. 3D Bioprinting Solutions/Vivax Bio
8.2.2. 3Dynamic Systems Ltd
8.2.3. Aether Inc.
8.2.4. Aspect Biosystems
8.2.5. Biobots
8.2.6. BioDan Group
8.2.7. Cellenion SASU
8.2.8. Cellink
8.2.9. Digilab Inc.
8.2.10. GeSIM
8.2.11. Microdrop Technologies GmbH
8.2.12. MicroFab
8.2.13. Organovo Holdings, Inc.
8.2.14. PeptiGelDesign Ltd
8.2.15. Poietis
8.2.16. Regemat 3D
8.2.17. SE3D
8.2.18. Sichuan Revotek Co. Ltd.

 

 

ページTOPに戻る

同社・類似レポート一覧

  • 同社同テーマのレポートはありません。

プレスリリース

[プレスリリース原文]

3D Bioprinting - Winners, losers, and the future of medicine

3D bioprinting is a catch-all term representing a raft of technologies as described in the recent IDTechEx report "3D Bioprinting 2014-2024: Applications, Markets and Players". Such is the potential of 3D bioprinting that the market could realistically reach a value of $6B by 2024.

3D bioprinting is a catch-all term representing a raft of technologies which involve the deposition ("printing") of living cells within an extra-cellular matrix (support material) which is designed to hold the cells in precise position in order that they proliferate and mature in a controlled manner - as described in the recent IDTechEx report 3D Bioprinting 2014-2024: Applications, Markets and Players. Such is the potential of 3D bioprinting that the market could realistically reach a value of $6B by 2024.

Each 3D bioprinting technology, including those which are already commercial and those which are currently in development, are detailed and a SWOT analysis presented for each. Key players, their technology-type, and the application areas on which they are currently focused are defined. All applications and potential applications, together with the challenges associated to each, are also discussed and a timeline for each presented.

The ultimate aim of 3D bioprinting is to replicate live 3-dimensional tissue cultures which may be used for a number of purposes. An early use of the technology for example, is likely to be the examination of cell response to external stimuli in an environment which more closely mimics that within the human body. The latter may be new drugs which are under investigation through the drug discovery process, or consumer products containing novel ingredients which may no longer be tested on animals within the EU. For the long term, hopes are high that entire human organs might be printed, eliminating the need for human donors, together with the lengthy waiting lists for transplants on which many patients die before a suitable organ can be procured. The outlook for and progress towards 3D printing of organs are discussed in depth.

The report, informed by seven in-depth interviews with experts in the field, discusses the challenges, technical and otherwise, faced by the 3D bioprinter developers. For example, a major challenge currently faced by companies working in this area regards lack of private investment, as many venture capital funds operating in the biotechnology arena tend to prefer low-risk, quick-win technologies. This will potentially delay commercial applications which could save lives, in spite of the huge addressable markets for 3D bioprinting, as given in fig 1.

Figure 1: Addressable markets for 3D bioprinting (numbers in US$B) - 3D Bioprinting 2014-2024 (IDTechEx)
Shorter and more efficient paths to new drug discovery should have a knock-on effect across the medical sector in fact, as the rates of drugs passing the clinical (human volunteer testing) phase are expected to increase, reducing the average cost of drug development and leading to cheaper medicines in the future. The report presents this innovation funnel for pharmaceutical development.

Regulatory hurdles will need to be overcome if the technology is to be applied in a clinical, as opposed to a research, environment however, although many 3D bioprinting companies hope that these hurdles will be lowered where the clinical applications involve the generation of tissue for graft or implant purposes which have been cultured from the patient's own cells. This remains something of a grey area nonetheless, as becomes clear through the company interviews presented, where opinions interestingly differ regarding this matter.

Of course there will also be losers in this scenario, these will include those companies:

  • specialising in the provision of 2D assays,

  • supplying animals for laboratory testing purposes,

  • manufacturing implants,

  • supplying medical devices such as dialysis machines, and

  • pharmaceutical developers supplying, for example, immune suppressant drugs.

Such organisations should have a clear interest in reading the report and understand the threat posed to their respective businesses and within which timeframe.

In the report, a number of scenarios are presented in terms of diffusion of the technology through the relevant application areas (see fig 2). As can be seen, for the next 5 year period, it is to be expected that 3D bioprinting enterprises will remain largely loss-making, with negligible revenues. Thereafter however, and subsequent to demonstration of the superior predictive value of 3D versus 2D assays, the market is expected to grow rapidly as the value of 3D bioprinting begins to manifest.

Figure 2: Scenario based market forecasts for 3D bioprinting - 3D Bioprinting 2014-2024 (IDTechEx)
It is important not to neglect the human benefits of 3D bioprinting of course, as the technology stands to improve the quality of life for countless patients and in the longer run, possibly even save lives. The elimination of the suffering of countless laboratory animals is also only to be applauded. Whether however improved patient outcomes reduce the burden on already overloaded health systems worldwide, or increases overheads as populations live longer, is a question yet to be answered.

 

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問い合せは、お電話・メール・WEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問い合せはこちらのフォームから承ります

office@dri.co.jp

このレポートへのお問い合せ

03-3582-2531

電話お問い合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る